AVIR Atea Pharmaceuticals Inc
3,171
$3.67
$0.06
(1.66%)
| Watchers | 3,171 |
| 52-Wk Low | $2.77 |
| 52-Wk High | $4.60 |
| Market Cap | $309.1M |
| Volume | 141,116.00 |
| 52-Wk High | $4.60 |
| 52-Wk Low | $2.77 |
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsGlobe Newswire • 2 months ago
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals...
Share to Feed
Federated Hermes Inc. decreased its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR Free Report) by 0.8% during the 3rd quarter, according to the company in its most recent 13F filing with...
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript...
Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400...
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ( Atea ), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR Free Report) Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Atea Pharmaceuticals in a research note...
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR Free Report) Analysts at Leerink Partnrs reduced their FY2023 earnings per share (EPS) estimates for Atea Pharmaceuticals in a report released...
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR Free Report) Investment analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for shares of Atea Pharmaceuticals in a report...
SG Americas Securities LLC bought a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR Free Report) in the third quarter, according to its most recent filing with the Securities and...
A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrollment Surpassed 650...